Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Repeated dose toxicity: oral

Currently viewing:

Administrative data

Endpoint:
short-term repeated dose toxicity: oral
Type of information:
read-across based on grouping of substances (category approach)
Adequacy of study:
key study
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study
Justification for type of information:
See IUCLID section 13 for category and read across justification

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
2020

Materials and methods

Test guideline
Qualifier:
according to guideline
Guideline:
OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
GLP compliance:
yes (incl. QA statement)

Test material

Constituent 1
Chemical structure
Reference substance name:
Lithium myristate
EC Number:
243-743-8
EC Name:
Lithium myristate
Cas Number:
20336-96-3
Molecular formula:
C14H28O2.Li
IUPAC Name:
lithium myristate
Test material form:
other: Solid salt prepared in situ in medicinal white oil for dosing
Details on test material:
- Form of test item: Prepared in situ
- Vehicle: Medicinal White Oil
- Concentration in vehicle: X % w/w

Test animals

Species:
rat

Results and discussion

Effect levels

Remarks on result:
other: Test ongoing

Target system / organ toxicity

Critical effects observed:
not specified

Applicant's summary and conclusion

Conclusions:
The short-term repeat dose toxicity of lithium myristate was determined to be
Executive summary:

The short-term repeat dose toxicity of lithium myristate to rats was determined in a GLP-compliant study following OECD guideline 422.